Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Vingerhoets, J; Calvez, V; Flandre, P; Marcelin, A G; Ceccherini-Silberstein, F; Perno, C F; Mercedes Santoro, M; Bateson, R; Nelson, M; Cozzi-Lepri, A; Grarup, J; Lundgren, J; Incardona, F; Kaiser, R; Sonnerborg, A; Clotet, B; Paredes, R; Günthard, Hf; Ledergerber, B; Hoogstoel, A; Nijs, S; Tambuyzer, L; Lavreys, L; Opsomer, M; Etravirine Cohort Study Group (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 16(5):297-306.

Cozzi-Lepri, A; Paredes, R; Phillips, A N; Clotet, B; Kjaer, J; Von Wyl, V; Kronborg, G; Castagna, A; Bogner, J R; Lundgren, J D (2012). The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Medicine, 13(1):62-72.

Wittkop, L; Günthard, H F; de Wolf, F; Dunn, D; Cozzi-Lepri, A; de Luca, A; Kücherer, C; Obel, N; von Wyl, V; Masquelier, B; Stephan, C; Torti, C; Antinori, A; García, F; Judd, A; Porter, K; Thiébaut, R; Castro, H; van Sighem, A I; Colin, C; Kjaer, J; Lundgren, J D; Paredes, R; Pozniak, A; Clotet, B; Phillips, A; Pillay, D; Chêne, G (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, 11(5):363-371.

Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, J D (2010). History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Medicine, 11(7):469-478.

Johnson, V A; Brun-Vezinet, F; Clotet, B; Gunthard, H F; Kuritzkes, D R; Pillay, D; Schapiro, J M; Richman, D D (2010). Update of the Drug Resistance Mutations in HIV-1: December 2010. Topics in HIV Medicine, 18(5):156-163.

Johnson, V A; Brun-Vezinet, F; Clotet, B; Gunthard, H F; Kuritzkes, D R; Pillay, D; Schapiro, J M; Richman, D D (2009). Update of the drug resistance mutations in HIV-1: December 2009. Topics in HIV Medicine, 17(5):138-145.

Johnson, V A; Brun-Vezinet, F; Clotet, B; Gunthard, H F; Kuritzkes, D R; Pillay, D; Schapiro, J M; Richman, D D (2008). Update of the Drug Resistance Mutations in HIV-1: December 2008. Topics in HIV Medicine, 16(5):138-145.

Hirsch, M S; Günthard, H F; Schapiro, J M; Brun-Vézinet, F; Clotet, B; Hammer, S M; Johnson, V A; Kuritzkes, D R; Mellors, J W; Pillay, D; Yeni, P G; Jacobsen, D M; Richman, D D (2008). Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clinical Infectious Diseases, 47(2):266-285.

Opravil, M; Sasadeusz, J; Cooper, D A; Rockstroh, J K; Clumeck, N; Clotet, B; Montaner, J; Torriani, F J; Depamphilis, J; Dieterich, D T (2008). Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(1):36-49.

Johnson, V A; Brun-Vezinet, F; Clotet, B; Gunthard, H F; Kuritzkes, D R; Pillay, D; Schapiro, J M; Richman, D D (2008). Update of the drug resistance mutations in HIV-1: Spring 2008. Topics in HIV Medicine, 16(1):62-68.

This list was generated on Thu Nov 23 16:32:49 2017 CET.